BioSpace News Archive

Sarepta Therapeutics Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, and the University of Florida today announced a strategic collaboration to enable cutting-edge research for novel genetic medicines. Through the agreement, Sarepta will fund multiple research programs at the University, and will have an exclusive option to further develop any new therapeutic compounds that result from the

RenovaCare, Inc. (Symbol: RCAR; www.renovacareinc.com), developer of patented technologies for spraying self-donated stem cells for the regeneration of skin and other organs and tissues, today announced that the US Food and Drug Administration (FDA) conditionally approved the Company’s Investigational Device Exemption (IDE) application to conduct a clinical trial to evaluate the safety and feasibility of autologous stem cells rendered by its Ce

PainTEQ, a leading medical device innovator, launched a first of its kind biomechanical study this month that explores the treatment of sacroiliac (SI) joint pain through a minimally invasive outpatient procedure using a posterior approach.

CEL-SCI Corporation (NYSE American: CVM) today reported financial results for the quarter ended June 30, 2020 and provided an update on clinical developments: CEL-SCI reached the targeted threshold of 298 events (deaths) required to conduct the data evaluation for its global pivotal Phase 3 head and neck cancer study of Multikine* (Leukocyte Interleukin, Inj.) immunotherapy. The study is currently in the database l

Revance Announces Two Peer-Reviewed Publications Reporting Safety and Efficacy Results from the SAKURA 3 Open-Label Safety Study in Dermatologic Surgery - The SAKURA 3 safety and efficacy results are consistent with those observed in SAKURA 1 and SAKURA 2 studies for DaxibotulinumtoxinA for Injection in the treatment of glabellar (frown) lines – NEWARK, Calif.--( BUSINESS WIRE )-- Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company fo

Company Plans to File Q2 2020 10-Q on August 13, 2020 Save the Date: Company to host virtual disease awareness event on October 20, 2020 focused on cancer therapy-related diarrhea

Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, US: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce, further to its press release of June 12, 2020, that under its sponsored research partnership agreement entered with the Reed Research Group out of the University of Wisconsin-Madison to evaluate novel formulations of psilocybi

Effective June 1, 2020, List Biological Laboratories, Inc. has reorganized their management team to better apply the wide-ranging skills of their executives.

Coming this September, Livestream #Act4Impact Fundraiser Hosted by Queen Latifah Will Entertain and Do Good

First participant dosed in Phase 1 study of SAB-185 for COVID-19 in healthy volunteers Phase 1b clinical trial evaluating the safety and pharmacological activity of SAB-185 in COVID-19 patients slated to start mid-August Novel proprietary technology platform leverages the native human immune response offering a differentiated high-potency therapeutic option to address virus mutations amidst ongoing pandemic